|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology显示文摘AIM:To assess human epidermal growth factor receptor-2 (HER2)-status in gastric cancer and matched lymph node metastases by immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH).METHODS:120 cases of primary gastric carcinomas and 45 matched lymph node metastases from patients with full clinicopathological features were mounted onto multiple-punch and single-punch tissue microarrays,respectively,and examined for HER2 overexpression and gene amplification by IHC and CISH.RESULTS:Twenty-four tumors (20%) expressed HER2 immunohistochemically.An IHC score of ≥ 2+ was observed in 20 tumors (16.6%).HER2 amplification was detected by CISH in 19 tumors (15.8%) and in their matched lymph node metastases.A high concordancerate was found between HER2 positivity (as detected by IHC) and HER2 gene amplification (as detected by CISH),since 19 of the 20 IHC positive cases were amplified (95%).All amplified cases had 2+ or 3+ IHC results.Amplification was associated with intestinal phenotype (P < 0.05).No association with grading,staging or survival was found.CONCLUSION:In gastric cancer,HER2 amplification is the main mechanism for HER2 protein overexpression and is preserved in lymph node metastases. | Dimitrios Tsapralis Ioannis Panayiotides George Peros Theodore Liakakos Eva Karamitopoulou | 2012 | World Journal of Gastroenterology2012，18，2： | 8 |
| 2 | TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer显示文摘BACKGROUND Patients with stage II-III colorectal cancer (CRC) treated with adjuvant chemotherapy, gain a 25% survival benefit. In the context of personalized medicine, there is a need to identify patients with CRC who may benefit from adjuvant chemotherapy. Molecular profiling could guide treatment decisions in these patients. Thymidylate synthase (TYMS) gene polymorphisms, KRAS and BRAF could be included in the molecular profile under consideration. AIM To investigate the association of TYMS gene polymorphisms, KRAS and BRAF mutations with survival of CRC patients treated with chemotherapy.METHODS A retrospective study studied formalin-fixed paraffin-embedded tissues (FFPEs) of consecutive patients treated with adjuvant chemotherapy during January/2005-January/2007. FFPEs were analysed with PCR for the detection of TYMS polymorphisms, mutated KRAS (mKRAS) and BRAF (mBRAF). Patients were classified into three groups (high, medium and low risk) according to 5’UTR TYMS polymorphisms Similarly, based on 3’UTR polymorphism ins/loss of heterozygosity (LOH) patients were allocated into two groups (high and low risk of relapse, respectively). Cox regression models examined the associated 5- year survival outcomes. RESULTS One hundred and thirty patients with early stage CRC (stage I-II: 55 patients;stage III 75 patients;colon: 70 patients;rectal: 60 patients) were treated with surgery and chemotherapy. The 5-year disease free survival and overall survival rate was 61.6% and 73.9% respectively. 5’UTR polymorphisms of intermediate TYMS polymorphisms (2RG/3RG, 2RG/LOH, 3RC/LOH) were associated with lower risk for relapse [hazard ratio (HR) 0.320, P = 0.02 and HR 0.343, P = 0.013 respectively] and death (HR 0.368, P = 0.031 and HR 0.394, P = 0.029 respectively). The 3’UTR polymorphism ins/LOH was independently associated with increased risk for disease recurrence (P = 0.001) and death (P = 0.005). mBRAF (3.8% of patients) was associated with increased risk of death (HR 4.500, P = 0.022) whereas mKRAS (39% of patients) not. CONCLUSION Prospective validating studies are required to confirm whether 2RG/3RG, 2RG/LOH, 3RC/LOH, absence of ins/LOH and wild type BRAF may indicate patients at lower risk of relapse following adjuvant chemotherapy. | Anastasios Ntavatzikos Aris Spathis Paul Patapis Nikolaos Machairas Georgia Vourli George Peros Iordanis Papadopoulos Ioannis Panayiotides Anna Koumarianou | 2019 | World Journal of Gastrointestinal Oncology2019，11，7： | 5 |
| 3 | Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer显示文摘AIM To investigate the impact of thymidylate synthase(TYMS), KRAS and BRAF in the survival of metastatic colorectal cancer(m CRC) patients treated with chemotherapy. METHODS Clinical data were collected retrospectively from records of consecutive patients with m CRC treated with fluoropyrimidine-based chemotherapy from 1/2005 to 1/2007. Formalin-fixed paraffin-embedded tissues were retrieved for analysis. TYMS genotypes were identified with restriction fragment analysis PCR, while KRAS and BRAF mutation status was evaluated using real-time PCR assays. TYMS gene polymorphisms of each of the 3' untranslated region(UTR) and 5'UTR were classified into three groups according to the probability they have for high, medium and low TYMS expression(and similar levels of risk) based on evidence from previous studies. Univariate and multivariate survival analyses were performed.RESULTS The analysis recovered 89 patients with m CRC(46.1% de novo metastatic disease and 53.9% relapsed). Of these, 46 patients(51.7%) had colon cancer and 43(48.3%) rectal cancer as primary. All patients were treated with fluoropyrimidine-based chemotherapy(5FU or capecitabine) as single-agent or in combination with irinotecan or/and oxaliplatin or/and bevacizumab. With a median follow-up time of 14.8 mo(range 0-119.8), 85 patients(95.5%) experienced disease progression, and 63 deaths(70.8%) were recorded. The 3-year and 5-year OS rate was 25.4% and 7.7% while the 3-year progression-free survival rate was 7.1%. Multivariate analysis of TYMS polymorphisms, KRAS and BRAF with clinicopathological parameters indicated that TYMS 3'UTR polymorphisms are associated with risk for disease progression and death(P < 0.05 and P < 0.03 respectively). When compared to tumors without any del allele(genotypes ins/ins and ins/loss of heterozygosity(LOH) linked with high TYMS expression) tumors with del/del genotype(low expression group) and tumors with ins/del or del/LOH(intermediate expression group) have lower risk for disease progression(HR = 0.432, 95%CI: 0.198-0.946, P < 0.04 and HR = 0.513, 95%CI: 0.287-0.919, P < 0.03 respectively) and death(HR = 0.366, 95%CI: 0.162-0.827, P < 0.02 and HR = 0.559, 95%CI: 0.309-1.113, P < 0.06 respectively). Additionally,KRAS mutation was associated independently with the risk of disease progression(HR = 1.600, 95%CI: 1.011-2.531, P < 0.05). The addition of irinotecan in 1st line chemotherapy was associated independently with lower risk for disease progression and death(HR = 0.600, 95%CI: 0.372-0.969, P < 0.04 and HR = 0.352, 95%CI: 0.164-0.757, P < 0.01 respectively).CONCLUSION The TYMS genotypes ins/ins and ins/LOH associate with worst prognosis in m CRC patients under fluoropyrimidine-based chemotherapy. Large prospective studies are needed for validation of our findings. | Anastasios Ntavatzikos Aris Spathis Paul Patapis Nikolaos Machairas George Peros Stefanos Konstantoudakis Danai Leventakou Ioannis G Panayiotides Petros Karakitsos Anna Koumarianou | 2017 | World Journal of Gastroenterology2017，23，32： | 4 |
| 4 | 结肠的腺癌和麦芽淋巴瘤的同时的出现: 一系列三个盒子显示文摘 Simultaneous development of adenocarcinoma and primary B cell lymphoma of mucosa-associated lymphoid tissue(MALT) lymphoma of the colon is rare;only one case has so far been reported out of 13 cases with the coexistence of colonic adenocarcinoma with involvement of the colon by lymphoma.We hereby present three more cases,two females(aged 75 and 71 years) and a male(aged 72 years).All three underwent colectomy based on a preoperative biopsy revealing colonic carcinoma.Histological examination of the resection specimens disclosed a colonic adenocarcinoma in two cases,whereas a tubulovillous adenoma with superficial foci of intraepithelial adenocarcinoma was seen in the thirdcase.Moreover,in all three cases,a coexisting MALT lymphoma was diagnosed in the colon(1 case),in both colon and adjacent lymph nodes(1 case) or in colonic lymph nodes and omentum(1 case).In the last case,a post-operative bone marrow biopsy revealed extensive infiltration of the bone marrow,due to which the patient received postoperative chemotherapy.Diagnostic and treatment issues are briefly discussed. | Theodoros Argyropoulos Periklis Foukas Maria Kefala Panagiotis Xylardistos Sotirios Papageorgiou Nikolaos Machairas Evmorfia Boltetsou Anastasios Machairas Ioannis G Panayiotides | 2012 | World Journal of Gastrointestinal Oncology2012，4，4： | 4 |
| 5 | Nuclear morphometry of the myocardial cells as a diagnostic tool in cases of sudden death due to coronary thrombosis显示文摘 | Lazaros GA Stefanaki KS Panayiotides IG | 1998 | Forensic Science International1998，96，： | 1 |
| 6 | nevus lipomatosus cutaneous superficialis (Hoffmann-Zurhel le)with localized scleroderma like appearance显示文摘 | Ioannidou DJ Stefanidou MP Panayiotides JG | 2001 | Int J Dermatol2001，40，1： | 1 |
| 7 | bcl-2 and Box expression in human endometriotic and adenomyotic tissues显示文摘 | Goumenou A Panayiotides I Matalliotakis I | 2001 | Eur J Obstet Gynecol Reprod Biol2001，99，2： | 1 |
| 8 | Bcl-2 and Bax expression in human endometriotic and adenomyotic tissues显示文摘 | Goumenou A Panayiotides I Matalliotakis I | 2001 | Eur J Obstet Gynecol Reprod Biol2001，99，2： | 1 |
| 9 | Retiform hemangioendothelioma presenting as bruise-like plaque in an adult woman 显示文摘 | loannidou D Panayiotides J Krasagakis K | 2006 | Int J Dermatol2006，45，1： | 1 |
| 10 | Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer显示文摘 | Karamitopoulou E Zlobec I Panayiotides I | 2011 | Hum Pathol2011，42，12： | 1 |
| 11 | Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer显示文摘 | Eva Karamitopoulou Inti Zlobec Ioannis Panayiotides Efstratios S. Patsouris George Peros George Rallis Christos Lapas Petros Karakitsos Luigi M. Terracciano Alessandro Lugli | 2011 | Human Pathology2011，，12： | 1 |
| 12 | Different HLA-DR expression in endometriotic and adenomyotic lesions:correlation with transvaginal ultasonography finding显示文摘 | Koumantakia EE Panayiotides JG | 2009 | Arch Gynecol Obstet2009，8，： | 1 |
| 13 | Effect of testis nondescent or orchidopexy on antisperm antibodies and testis histology in rats显示文摘 | Petros Mirilas Ioannis Panayiotides Anastasia Mentessidou Georgios Mavrogenis Elissaios Kontis Panagiotis Lainas Marta De Almeida | 2010 | Fertility and Sterility2010，，4： | 1 |
| 14 | Different HLA-DR expression in endometriotic and adenomyotic lesions: correlation with transvaginal ultrasonography findings显示文摘 | E. E. Koumantakis J. G. Panayiotides A. G. Goumenou E. Ch. Ziogos A. Margariti V. Kalapothaki Ioannis M. Matalliotakis | 2010 | Archives of Gynecology and Obstetrics2010，，5： | 1 |
| 15 | Different HLA-DR expression in endometriotic and adenomyotic lesions: correlation with transvaginal ultrasonography findings 显示文摘 | Koumantakis EE Panayiotides JG Goumenou AG | 2010 | Areh Gynecol Obstet2010，281，5： | 1 |
| 16 | Immunohistochemical expression of p53,MDM2,and p21 Wafl oncoproteins in endometriomas but not adenomyosis显示文摘 | Goumenou A Panayiotides I Neal G | 2005 | J Soe Gynecol Invest2005，12，4： | 1 |
| 17 | Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus显示文摘 | Ioannidou DJ Panayiotides JG | 1999 | Br J Dermatol1999，141，6： | 1 |
| 18 | Poikiloderma of Civatte: a histopathological and ultrastructural study显示文摘 | Katoulis AC Stavrianeas NG Panayiotides JG | 2007 | Dermatology2007，214，2： | 1 |
| 19 | Different HLA-DR expression in endometriotic andadenomyotic lesions: correlation with transvaginalultrasonography findings显示文摘 | Koumantakis EE Panayiotides JG Goumenou AG | 2010 | Arch Gynecol Obstet2010，281，5： | 1 |
| 20 | An giosarcoma of the maxillary sinus显示文摘 | Velegraki s G A Panayiotides J G Skoulakis C E | 2000 | J Laryngol Otol2000，114，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员